Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioVie Inc. (NASDAQ: BIVI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical issuer, BioVie files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and registration statements such as Form S-1 related to securities offerings.
Through these filings, BioVie describes its clinical-stage programs in neurological and neurodegenerative disorders and advanced liver disease, including development of bezisterim (NE3107) for Alzheimer’s disease, Parkinson’s disease and long COVID, and BIV201, a continuous infusion terlipressin therapy for complications of advanced liver cirrhosis. Investors can review risk factors, clinical trial descriptions, regulatory designations such as Orphan Drug and Fast Track status for BIV201, and discussions of how neuroinflammation and insulin resistance are believed to relate to the company’s target indications.
Current reports on Form 8-K capture material events such as underwritten public offerings of units and warrants, the listing of warrants under the symbol BIVIW, the implementation of a one-for-ten reverse stock split, amendments to the 2019 Omnibus Equity Incentive Plan, and changes in the composition of the board of directors. Registration statements and their amendments detail the terms of securities being offered, including units, pre-funded warrants, and warrants, and provide additional narrative on BioVie’s business and clinical pipeline.
On Stock Titan, these SEC documents are presented with real-time updates from EDGAR and AI-powered summaries that help explain the key points of lengthy filings. Users can quickly identify items related to clinical trial progress, capital raising transactions, equity incentive plans, and corporate governance without reading every page. Forms 10-K and 10-Q can be reviewed with AI-generated highlights of segment information and risk disclosures, while Form 4 and related ownership filings, when available, can be used to monitor insider equity activity.
This centralized view of BioVie’s SEC filings allows investors and researchers to track how the company describes its neurology and liver disease programs, financing activities, and corporate actions over time, with AI tools to make complex regulatory language more accessible.
BioVie held a Special Meeting of stockholders on June 23, 2025, with 10,971,031 shares represented out of 18,570,726 outstanding shares of Class A common stock. Two key proposals were voted on:
Proposal 1: Reverse Stock Split Authorization The stockholders approved granting the Board authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, to be executed within one year. The voting results showed:
- For: 8,664,435 shares (79%)
- Against: 2,200,874 shares
- Abstain: 105,722 shares
Proposal 2: Meeting Adjournment Authority Shareholders approved discretionary authority to adjourn the meeting if needed to gather more proxies, with:
- For: 8,788,143 shares (80%)
- Against: 2,033,834 shares
- Abstain: 149,054 shares